Vaginal Antifungals Market by Product, Route of Administration, Indication, Distribution Channel & Region | Forecast From 2023 to 2033

<p>The global <strong>vaginal antifungals market </strong>enjoys a valuation of US$ 1.09 Billion in 2022, and it is further projected to expand at a CAGR of 4.5% over the forecasted years. According to a recent study by Future Market Insights, Polygenes are leading the market with a share of about 49.0% in the year 2022, within the global market.</p><table><tbody><tr><th scope='row'>Data Points</th><td>Market Insights</td></tr><tr><th scope='row'>Market Value 2022</th><td>US$ 1.09 Billion</td></tr><tr><th scope='row'>Market Value 2033</th><td>US$ 1.76 Billion</td></tr><tr><th scope='row'>CAGR 2023 to 2033</th><td>4.5%</td></tr><tr><th scope='row'>Market Share of Top 5 Countries</th><td>61.7%</td></tr><tr><th scope='row'>Key Market Players</th><td>Pfizer Inc., Bausch Health Companies Inc., ANI Pharmaceuticals, Inc., Hikma Pharmaceuticals Plc, Lupin Limited, Mycovia Pharmaceuticals, Inc., Glenmark Pharmaceuticals Limited, Unique Pharmaceuticals, PEPTONIC Medical AB, Aurobindo Pharma Limited, Dr. Reddy&#39;s Laboratories, SCYNEXIS Inc., Basilea Pharmaceutica Ltd., Astellas Pharma Inc., Grupo Ferrer Internacional, S.A.Pacgen Life Science Corporation, NovaDigm Therapeutics, Inc., Cidara Therapeutics, Inc., Amplyx Pharmaceuticals Inc.</td></tr></tbody></table><p>Report Scope as per Vaginal Antifungals Industry Analysis</p><table><tbody><tr><th scope='row'>Attribute</th><td>Details</td></tr><tr><th scope='row'>Forecast Period</th><td>2018 to 2022</td></tr><tr><th scope='row'>Historical Data Available for</th><td>2023 to 2033</td></tr><tr><th scope='row'>Market Analysis</th><td>US$ Million for Value</td></tr><tr><th scope='row'>Key Regions Covered</th><td>North America, Latin America, Europe, South Asia, East Asia, Oceania, and the Middle East &amp; Africa</td></tr><tr><th scope='row'>Key Countries Covered</th><td>The USA, Canada, Brazil, Mexico, Argentina, The United kingdom, Germany, Italy, Russia, Spain, France, Benelux, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, T&uuml;rkiye, GCC Countries and South Africa</td></tr><tr><th scope='row'>Key Market Segments Covered</th><td>Product, Route of Administration, Indication, Distribution Channel, and Region</td></tr><tr><th scope='row'>Key Companies Profiled</th><td><ul><li>Pfizer Inc.</li><li>Bausch Health Companies Inc</li><li>ANI Pharmaceuticals, Inc.</li><li>Hikma Pharmaceuticals Plc</li><li>Lupin Limited</li><li>Mycovia Pharmaceuticals, Inc.</li><li>Glenmark Pharmaceuticals Limited</li><li>GSK plc.</li><li>Aurobindo Pharma Limited</li><li>Dr. Reddy&#39;s Laboratories</li><li>SCYNEXIS, Inc.</li><li>Basilea Pharmaceutica Ltd.</li><li>Astellas Pharma Inc.</li><li>Grupo Ferrer Internacional, S.A.</li><li>Pacgen Life Science Corporation</li><li>NovaDigm Therapeutics, Inc.</li><li>Cidara Therapeutics, Inc.</li><li>Amplyx Pharmaceuticals Inc.</li></ul></td></tr><tr><th scope='row'>Report Coverage</th><td>Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives</td></tr><tr><th scope='row'>Pricing</th><td>Available upon Request</td></tr></tbody></table>

<p>全球阴道抗真菌药物市场在2022年实现了10.9亿美元的估值，并预计在未来预测期内以4.5%的复合年增长率持续扩张。根据未来市场洞察力公司近期的研究报告，多基因产品在2022年占据了全球市场的约49.0%份额。</p><table><tbody><tr><th scope='row'>数据点</th><td>市场洞察</td></tr><tr><th scope='row'>2022年市场价值</th><td>10.9亿美元</td></tr><tr><th scope='row'>2033年市场价值</th><td>17.6亿美元</td></tr><tr><th scope='row'>2023至2033年复合年增长率</th><td>4.5%</td></tr><tr><th scope='row'>前五名国家市场占有率</th><td>61.7%</td></tr><tr><th scope='row'>主要市场参与者</th><td>辉瑞公司（Pfizer Inc.）、保诚健康公司（Bausch Health Companies Inc.）、ANI制药公司（ANI Pharmaceuticals, Inc.）、希克玛制药公司（Hikma Pharmaceuticals Plc）、鲁宾制药有限公司（Lupin Limited）、迈科维亚制药公司（Mycovia Pharmaceuticals, Inc.）、格兰马克制药有限公司（Glenmark Pharmaceuticals Limited）、独特制药公司（Unique Pharmaceuticals）、PEPTONIC医疗AB、澳文多制药有限公司（Aurobindo Pharma Limited）、雷迪博士实验室（Dr. Reddy's Laboratories）、SCYNEXIS公司（SCYNEXIS Inc.）、巴塞利亚制药公司（Basilea Pharmaceutica Ltd.）、阿斯利康制药公司（Astellas Pharma Inc.）、费雷尔国际集团（Grupo Ferrer Internacional, S.A.）、Pacgen生命科学公司（Pacgen Life Science Corporation）、诺瓦迪格制药公司（NovaDigm Therapeutics, Inc.）、西达拉治疗公司（Cidara Therapeutics, Inc.）、安普利克斯制药公司（Amplyx Pharmaceuticals Inc.）</td></tr></tbody></table><p>阴道抗真菌行业分析报告范围</p><table><tbody><tr><th scope='row'>属性</th><td>详情</td></tr><tr><th scope='row'>预测期</th><td>2018至2022年</td></tr><tr><th scope='row'>历史数据可提供</th><td>2023至2033年</td></tr><tr><th scope='row'>市场分析</th><td>以百万美元计的价值</td></tr><tr><th scope='row'>主要覆盖地区</th><td>北美、拉丁美洲、欧洲、南亚、东亚、大洋洲和中东及非洲</td></tr><tr><th scope='row'>主要覆盖国家</th><td>美国、加拿大、巴西、墨西哥、阿根廷、英国、德国、意大利、俄罗斯、西班牙、法国、比荷卢、印度、泰国、印度尼西亚、马来西亚、日本、中国、韩国、澳大利亚、新西兰、土耳其、海湾合作委员会国家及南非</td></tr><tr><th scope='row'>主要市场细分</th><td>产品、给药途径、适应症、分销渠道和地区</td></tr><tr><th scope='row'>主要公司简介</th><td><ul><li>辉瑞公司（Pfizer Inc.）</li><li>保诚健康公司（Bausch Health Companies Inc）</li><li>ANI制药公司（ANI Pharmaceuticals, Inc.）</li><li>希克玛制药公司（Hikma Pharmaceuticals Plc）</li><li>鲁宾制药有限公司（Lupin Limited）</li><li>迈科维亚制药公司（Mycovia Pharmaceuticals, Inc.）</li><li>格兰马克制药有限公司（Glenmark Pharmaceuticals Limited）</li><li>英国葛兰素史克公司（GSK plc.）</li><li>澳文多制药有限公司（Aurobindo Pharma Limited）</li><li>雷迪博士实验室（Dr. Reddy's Laboratories）</li><li>SCYNEXIS公司（SCYNEXIS, Inc.）</li><li>巴塞利亚制药公司（Basilea Pharmaceutica Ltd.）</li><li>阿斯利康制药公司（Astellas Pharma Inc.）</li><li>费雷尔国际集团（Grupo Ferrer Internacional, S.A.）</li><li>Pacgen生命科学公司（Pacgen Life Science Corporation）</li><li>诺瓦迪格制药公司（NovaDigm Therapeutics, Inc.）</li><li>西达拉治疗公司（Cidara Therapeutics, Inc.）</li><li>安普利克斯制药公司（Amplyx Pharmaceuticals Inc.）</li></ul></td></tr><tr><th scope='row'>报告覆盖</th><td>市场预测、竞争情报、DROT分析、市场动态和挑战、战略增长举措</td></tr><tr><th scope='row'>定价</th><td>根据要求提供</td></tr></tbody></table>